Empagliflozin protects against renal ischemia/reperfusion injury in mice
Abstract Renal ischemia/reperfusion (I/R) can induce acute kidney injury. Empagliflozin is a newly developed inhibitor of sodium-glucose cotransporter-2 (SGLT2) approved as an antidiabetic medication for patients with type 2 diabetes mellitus. Despite the established cardioprotective functions of em...
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | 論文 |
| 言語: | English |
| 出版事項: |
Nature Portfolio
2022-11-01
|
| シリーズ: | Scientific Reports |
| オンライン･アクセス: | https://doi.org/10.1038/s41598-022-24103-x |